ES2054484T3 - Composiciones farmaceuticas que contienen complejos de antigeno-anticuerpo, asi como la utilizacion de las mismas. - Google Patents
Composiciones farmaceuticas que contienen complejos de antigeno-anticuerpo, asi como la utilizacion de las mismas.Info
- Publication number
- ES2054484T3 ES2054484T3 ES91900689T ES91900689T ES2054484T3 ES 2054484 T3 ES2054484 T3 ES 2054484T3 ES 91900689 T ES91900689 T ES 91900689T ES 91900689 T ES91900689 T ES 91900689T ES 2054484 T3 ES2054484 T3 ES 2054484T3
- Authority
- ES
- Spain
- Prior art keywords
- antigen
- treatment
- well
- same
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE PRESENTA UN COMPUESTO FARMACEUTICO ADECUADO PARA SU ADMINISTRACIONA LOS SERES HUMANOS PARA LA PREVENCION O TRATAMIENTO DE ENFERMEDADES INMUNOLOGICAS, EL COMPUESTO INCLUYE: UN COMPLEJO INMUNE DE UN ANTIGENO Y UN ANTICUERPO PURIFICADO ESPECIFICO PARA EL MISMO, EL ANTIGENO ESTA SELECCIONADO ENTRE UN GRUPO QUE CONSTA DE LOS ANTIGENOS QUE PROVOCAN REACCIONES INMUNOLOGICAS PATOGENAS EN ENFERMEDADES AUTOINMUNES Y RECHAZO DE TRANSPLANTES, Y EL ANTIGENO Y EL ANTICUERPO ESTAN PRESENTES EN UNA PROPORCION MEDIANTE LA CUAL EL ANTICUERPO BLOQUEA ESENCIALMENTE TODOS LOS ENLACES DEL ANTIGENO; TAMBIEN SE PRESENTA UN PORTADOR O DILUYENTES FARMACOLOGICAMENTE ACEPTABLE. LA INVENCION TAMBIEN SUMINISTRA UN METODO PARA LA ADMINISTRACION DEL COMPUESTO PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES Y EL TRATAMIENTO O PREVENCION DE RECHAZOS EN TRANSPLANTES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46051490A | 1990-01-03 | 1990-01-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2054484T3 true ES2054484T3 (es) | 1994-08-01 |
Family
ID=23829022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91900689T Expired - Lifetime ES2054484T3 (es) | 1990-01-03 | 1990-12-31 | Composiciones farmaceuticas que contienen complejos de antigeno-anticuerpo, asi como la utilizacion de las mismas. |
Country Status (15)
Country | Link |
---|---|
US (1) | US7122380B1 (es) |
EP (1) | EP0508993B1 (es) |
JP (1) | JPH03227942A (es) |
AT (1) | ATE103495T1 (es) |
AU (1) | AU644400B2 (es) |
CA (1) | CA2015515C (es) |
DE (1) | DE69007799T2 (es) |
DK (1) | DK0508993T3 (es) |
ES (1) | ES2054484T3 (es) |
HU (1) | HUT62486A (es) |
IE (1) | IE65399B1 (es) |
NO (1) | NO922621L (es) |
PL (1) | PL288597A1 (es) |
PT (1) | PT96409A (es) |
WO (1) | WO1991009619A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620686A (en) * | 1990-09-28 | 1997-04-15 | British Technology Group Limited | Antigen-antibody conjugates |
DE69123256T2 (de) * | 1990-09-28 | 1997-06-12 | British Tech Group | Antigen-antikörperkonjugaten |
AU696560B2 (en) * | 1993-03-19 | 1998-09-10 | Fred D. Finkelman | Pharmaceutical compositions comprising a ligand complexed with a soluble receptor |
FR2728264B1 (fr) * | 1994-12-16 | 1997-01-31 | Rhone Poulenc Rorer Sa | Purification d'adn par formation de triple helice avec un oligonucleotide immobilise |
AUPO269996A0 (en) * | 1996-10-01 | 1996-10-24 | Walter And Eliza Hall Institute Of Medical Research, The | A method of prophylaxis and treatment |
AU1267501A (en) * | 1999-09-07 | 2001-04-10 | Bioserv Ag | Novel autogenous vaccines used to obtain an immune tolerance |
CA2526950C (en) | 2002-05-27 | 2012-06-26 | Leif Hakansson | Method for determining immune system affecting compounds |
JP2007502305A (ja) * | 2003-08-15 | 2007-02-08 | ザ ガバナーズ オブ ザ ユニバーシティー オブ カルガリー | 哺乳動物の抗原特異的抗体のレベルを操作するための組成物および方法 |
AU2011218660B2 (en) * | 2003-08-15 | 2011-12-15 | The Governors Of The University Of Calgary | Compositions and methods for manipulating levels of antigen-specific antibodies in a mammal |
SE0402536D0 (sv) | 2004-10-20 | 2004-10-20 | Therim Diagnostica Ab | Immunoregulation in cancer, chronic inflammatory and autoimmune diseases |
US8110347B2 (en) | 2005-04-15 | 2012-02-07 | Canimguide Therapeutics Ab | Diagnostic method for detecting cancer by measuring amount of cytokine like IL-6 |
GB2440528A (en) * | 2006-07-27 | 2008-02-06 | Ist Superiore Sanita | Antigen-antibody complexes |
ES2747363T3 (es) | 2007-05-08 | 2020-03-10 | Canimguide Therapeutics Ab | Estructuras inmunorreguladoras de proteínas que se encuentran normalmente |
WO2017218677A2 (en) * | 2016-06-14 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Identification and medical applications of anti-citrullinated-protein antibodies in rheumatoid arthritis |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140679A (en) | 1976-10-12 | 1979-02-20 | Research Corporation | Antigen-protein complex for blocking allergic reactions |
US4234569A (en) | 1978-10-04 | 1980-11-18 | The Johns Hopkins University | Production of aldehyde-treated allergen-containing substances |
DE2846412A1 (de) | 1978-10-25 | 1980-05-08 | Behringwerke Ag | Mittel zur behandlung allergischer reaktionen |
US4521405A (en) | 1982-05-17 | 1985-06-04 | John McMichael | Methods and materials for treatment of disease states involving immunological factors |
US4545986A (en) | 1982-06-22 | 1985-10-08 | Research Corporation | Timothy grass antigen specific anti-idiotypic antibodies |
US4564600A (en) | 1982-10-26 | 1986-01-14 | Majid Ali | Allergens and antibodies from allergen extracts and pooled serum |
US4702907A (en) | 1983-08-09 | 1987-10-27 | Cornell Research Foundation, Inc. | Process for inducing selective immunosuppression of antibodies |
US4681760A (en) | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
CA1282069C (en) | 1985-09-12 | 1991-03-26 | Damon L. Meyer | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
US4714759A (en) | 1985-12-02 | 1987-12-22 | Whitaker Jr Robert B | Immunotoxin therapy of allergy |
GB8608068D0 (en) | 1986-04-02 | 1986-05-08 | Cobbold S P | Monoclonal antibodies |
GB8610983D0 (en) | 1986-05-06 | 1986-06-11 | Connaught Lab | Enhancement of antigen immunogenicity |
EP0411017B1 (en) * | 1988-04-04 | 1996-03-06 | POTEMPA, Lawrence A. | Binding of immune complexes by modified forms of c-reactive protein |
-
1990
- 1990-04-26 CA CA002015515A patent/CA2015515C/en not_active Expired - Fee Related
- 1990-05-23 JP JP2133680A patent/JPH03227942A/ja active Pending
- 1990-12-21 IE IE469390A patent/IE65399B1/en not_active IP Right Cessation
- 1990-12-31 AT AT91900689T patent/ATE103495T1/de not_active IP Right Cessation
- 1990-12-31 DK DK91900689.0T patent/DK0508993T3/da active
- 1990-12-31 AU AU69626/91A patent/AU644400B2/en not_active Ceased
- 1990-12-31 HU HU9202214A patent/HUT62486A/hu unknown
- 1990-12-31 WO PCT/BE1990/000074 patent/WO1991009619A1/en active IP Right Grant
- 1990-12-31 DE DE69007799T patent/DE69007799T2/de not_active Expired - Fee Related
- 1990-12-31 EP EP91900689A patent/EP0508993B1/en not_active Expired - Lifetime
- 1990-12-31 ES ES91900689T patent/ES2054484T3/es not_active Expired - Lifetime
-
1991
- 1991-01-02 PT PT96409A patent/PT96409A/pt not_active Application Discontinuation
- 1991-01-03 PL PL28859791A patent/PL288597A1/xx unknown
-
1992
- 1992-07-02 NO NO92922621A patent/NO922621L/no unknown
-
1994
- 1994-05-13 US US08/242,076 patent/US7122380B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
HU9202214D0 (en) | 1992-10-28 |
HUT62486A (en) | 1993-05-28 |
AU644400B2 (en) | 1993-12-09 |
AU6962691A (en) | 1991-07-24 |
NO922621D0 (no) | 1992-07-02 |
EP0508993A1 (en) | 1992-10-21 |
CA2015515A1 (en) | 1991-07-03 |
EP0508993B1 (en) | 1994-03-30 |
PT96409A (pt) | 1991-10-15 |
ATE103495T1 (de) | 1994-04-15 |
US7122380B1 (en) | 2006-10-17 |
PL288597A1 (en) | 1991-08-12 |
IE65399B1 (en) | 1995-10-18 |
JPH03227942A (ja) | 1991-10-08 |
DE69007799T2 (de) | 1994-10-20 |
NO922621L (no) | 1992-09-02 |
DK0508993T3 (da) | 1994-05-09 |
IE904693A1 (en) | 1991-07-17 |
CA2015515C (en) | 1999-12-07 |
DE69007799D1 (de) | 1994-05-05 |
WO1991009619A1 (en) | 1991-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2054484T3 (es) | Composiciones farmaceuticas que contienen complejos de antigeno-anticuerpo, asi como la utilizacion de las mismas. | |
UA29494C2 (uk) | Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція | |
DE69033487D1 (de) | Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol | |
NO982062L (no) | Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav | |
GB2301366A (en) | Antibodies against E-selectin | |
FI972703A0 (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
HK1025738A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting tcell activation and proliferation | |
ATE205480T1 (de) | 2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten | |
EP0350690A3 (de) | Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente | |
ES2196150T3 (es) | Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion. | |
SG48816A1 (en) | Gonococcal anti-idiotypic antibodies and methods and compositions using them | |
DE3162128D1 (en) | Biologically active compounds, their obtention from human casein and compositions containing them | |
PT1331944E (pt) | Utilização de anticorpos monoclonais específicos para cd28 para a estimulação de células sanguíneas que não comportam qualquer cd28 | |
BG103416A (en) | Soluble lymphotoxin-beta receptors, antilymphotosoluble lymphotoxin- receptors, antilymphotoxin receptor antibodies and antilymphotoxin ligand antixin receptor antibodies and antilymphotoxin ligandbodies as therapeutical forms for the treatment of antibodies as therapeutical forms for the treatment of immunological diseases immunological diseases | |
MX9702926A (es) | L-eritrosilnucleosidos. | |
Strong et al. | Antigenic characterization of a T-CLL with heteroantisera and monoclonal antibodies: evidence for the T cell lineage of an Ia-positive, Fc-IgG--positive, suppressor-cell subpopulation. | |
DK0521057T3 (da) | Farmaceutiske midler indeholdende ipriflavon, fremgangsmåde til fremstilling deraf, og relativ terapeutisk anvendelse | |
FI20095269A (fi) | Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli | |
MX9702927A (es) | L-piranosilnucleosidos. | |
KR900005996A (ko) | 자기면역 질환의 치료 또는 예방을 위한 면역독소 | |
DE3850044D1 (de) | Azelastin-Embonat, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen, die als Wirkstoff Azelastin-Embonat enthalten. | |
DE59207362D1 (de) | Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
AP1638A (en) | Peptide mimics of conserved gonococcal epitopes and methods and compositions using them. | |
FR2646607B1 (fr) | Anticorps monoclonaux anti-b2 microglobuline | |
IT1254742B (it) | Impiego della beta-endorfina quale farmaco immunosoppressore nei trapianti d'organo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 508993 Country of ref document: ES |